Analysts’ Top Healthcare Picks: Rockwell Med (RMTI), Biogen (BIIB)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rockwell Med (RMTIResearch Report) and Biogen (BIIBResearch Report) with bullish sentiments.

Rockwell Med (RMTI)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rockwell Med, with a price target of $3.00. The company’s shares closed last Friday at $0.47, close to its 52-week low of $0.34.

According to TipRanks.com, Selvaraju has 0 stars on 0-5 stars ranking scale with an average return of -24.8% and a 20.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals.

Rockwell Med has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.

See today’s best-performing stocks on TipRanks >>

Biogen (BIIB)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Biogen, with a price target of $270.00. The company’s shares closed last Friday at $239.30, close to its 52-week low of $217.10.

According to TipRanks.com, Fein is a 3-star analyst with an average return of 1.6% and a 38.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Deciphera Pharmaceuticals, and Global Blood Therapeutics.

Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $290.00, a 23.4% upside from current levels. In a report issued on January 7, Truist Financial also maintained a Buy rating on the stock with a $343.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on RMTI: